Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has selected MolMed to develop a production process for an experimental gene therapy for adenosine deaminase deficiency - severe combined immune deficiency (ADA-SCID).
Subscribe to our email newsletter
As per the terms of the agreement, GSK is responsible to pay up to EUR5.5m to MolMed in revenues for a term of two-year.
Developed by the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), the gene therapy is in late stage clinical trials and was in-licensed by GSK to develop and commercialize the therapy.
MolMed chairman and CEO Claudio Bordignon said the company has expertise and know-how in the field of gene and cell therapy and this agreement with GSK is an important step on the way to provide gene therapy for patients with rare diseases.